Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm Group™ announced the successful achievement of a second development milestone on Spinomix’ two proprietary technologies, namely MagPhase™ and FibroTrap™. In conjunction with the terms of the investment agreement, Spinomix is to receive an undisclosed second tranche payment from Debiopharm.
Nasri Nahas, Spinomix’s new CEO, brings 20 years of experience in the biotech start-ups industry, from both the research and business perspectives. Over the course of his 12 years tenure as the CEO of Geneva Bioinformatics (GeneBio) SA, he lead GeneBio’s operations and successfully built an exceptional and highly motivated team of industry experts who grew the company from a start-up-like setting to an experienced, well-established and renowned organization.